Navigation Links
Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference
Date:11/26/2013

SAN DIEGO, Nov. 26, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Piper Jaffray Healthcare Conference in New York on Tuesday, December 3, 2013 at 12:00 p.m. ET/9:00 a.m. PT. Gregory I. Frost, Ph.D., President and Chief Executive Officer, Halozyme Therapeutics, will provide a corporate overview.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately 15 minutes prior to the presentation to register and download any necessary audio software.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com and follow us on Twitter @HaloTherapeutic.

Investor Contact:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com

Media Contact:
Nurha Hindi
Hill + Knowlton Strategies
818-522-8411
Nurha.Hindi@hkstrategies.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
2. Halozyme to Host Third Quarter 2013 Financial Results Conference Call
3. SWOG Initiates Randomized Phase 2 Clinical Trial of Halozymes PEGPH20 in Combination with modified FOLFIRINOX for Advanced Pancreatic Cancer
4. Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
5. Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to Halozyme from Roche
6. Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference
7. Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress
8. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
9. Halozyme Reports Second Quarter 2013 Financial Results
10. Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20
11. Halozyme to Host Second Quarter 2013 Financial Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , Jan. 23, 2017  Using Astute ... at high risk for acute kidney injury (AKI) ... by globally-recognized care guidelines significantly improved ... severe AKI more than 33 percent, according to ... the journal Intensive Care Medicine. ...
(Date:1/23/2017)... , January 23, 2017 Longer life expectancy ... in the global market for medical device technologies. BCC Research ... the Asia-Pacific region, should see strong growth due ... rising disposable incomes. Continue Reading ... ...
(Date:1/23/2017)... 2017 NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical collaboration agreement with the Children,s Hospital of ... M.D., a US key opinion leader in the mitochondrial medicine ... ... from NeuroVive,s research program, NVP015, in certain experimental disease models. ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... ... a time when many people celebrate romance and love by giving cards, candy, flowers or ... present, Atlanta-based Perimeter Plastic Surgery is offering a Valentine’s Day special: Spend $100 ... $50 free. , “A lot of people just buy the more predictable gift of ...
(Date:1/22/2017)... ... January 22, 2017 , ... "Photo Cloud allows FCPX users ... beautiful 3D slideshow with complete ease," said Christina Austin - CEO of Pixel Film ... in the FCPX timeline. Presets include scenes with one, three, four or ...
(Date:1/21/2017)... ... , ... Salveo for life, a company that distributes an effervescent lime-flavored drink ... as part of its presence to expand its market reach. , Using a formula ... of nasty toxins as a result of drinking alcohol, eliminating those toxins quickly, whilst ...
(Date:1/21/2017)... ... January 21, 2017 , ... Phytocéane invites you to ... the rest of the world with ZANZIBAR SHOWER GEL. Inspired by the beauty of ... Virgin Coconut Oil and moisturizing vegetal coral to create this gentle, crystal-clear shower gel ...
(Date:1/21/2017)... ... January 21, 2017 , ... Santa Rosa Orthopaedics (SRO) is ... at 167 Lynch Creek Way. The Petaluma office features three comfortable patient exam ... rehabilitation services and on-site x-ray services. Two multi-specialist orthopaedic surgeons Dr. Neema ...
Breaking Medicine News(10 mins):